Zevia PBC Stock Rises 25% in Two Weeks Amid Short-Term Buy Signals

Zevia PBC stock (ISIN: US98971P1021) climbs in a strong rising trend, with analysts forecasting up to 28% upside in three months, drawing attention from value-seeking investors.

Zevia PBC stock (ISIN: US98971P1021), the NYSE-listed maker of zero-calorie, plant-based sweetened beverages, has surged 24.62% over the past two weeks as of March 11, 2026, entering a robust short-term rising trend. Trading at around $3.29 with reduced volume on the latest session, the shares signal potential for further gains, supported by moving averages and technical indicators despite lingering challenges from prior quarters. This momentum comes amid a broader consumer staples sector focus on healthier alternatives, positioning Zevia as a speculative play for investors eyeing recovery in the functional beverage space.

As of: 13.03.2026

By Elena Voss, Senior Beverage Sector Analyst - Tracking sustainable consumer trends for European investors.

Current Market Snapshot for Zevia PBC

The Zevia PBC stock closed flat on March 11, 2026, at approximately $3.29 after a session with 332,000 shares traded, down 199,000 from prior volume, which technical analysts view as a positive divergence. Over the last 10 days, the stock rose on six occasions, building momentum within a wide rising channel that suggests continued upside. Support levels cluster around $3.25 from accumulated volume, with resistance at $3.39, implying intraday volatility of up to 6.3% on the next session.

Longer-term, the stock remains down 28.04% since late January 2026, reflecting ongoing profitability hurdles in a competitive soda market. Yet, short-term buy signals from moving averages, where the short-term average exceeds the long-term, dominate current sentiment. A MACD sell signal persists, but volume-price dynamics favor bulls in the near term.

Technical Forecast Points to 28% Upside

Analysts project a 28.21% rise over the next three months, with 90% probability of prices between $3.57 and $5.01, driven by the prevailing uptrend. Fibonacci levels highlight resistance at $3.43 (R3) and support at $3.21 (S3), while accumulated volume supports buying at $3.25. The stock's score of 2.993 rates it a buy candidate, unchanged recently, appealing to traders comfortable with high volatility and low liquidity periods.

For European investors, Zevia PBC trades over-the-counter in limited volumes on Xetra, but the NYSE primary listing offers direct access via most DACH brokers. With the euro strengthening against the dollar in early 2026, currency tailwinds could enhance returns for Swiss and German portfolios diversified into US consumer plays. However, the stock's beta implies amplified swings tied to US retail sales data.

Zevia's Business Model in the Zero-Sugar Beverage Arena

Zevia PBC operates as a public benefit corporation, producing stevia-sweetened sodas, energy drinks, and mixers free of sugar, calories, and artificial colors, distributed across major US retailers like Walmart and Kroger. Unlike traditional soft drink giants relying on high-fructose corn syrup, Zevia's plant-based formula targets health-conscious consumers amid rising obesity concerns and sugar taxes. Revenue stems primarily from branded sales, with growth hinging on velocity in existing stores and new listings.

Key metrics for beverage investors include retail take rate, distribution points, and gross margins from concentrate production. Q2 2025 results showed EPS losses but improving margins, signaling operating leverage as volumes stabilize post-pandemic shifts. For DACH investors familiar with functional drinks like Fritz-Kola or Rivella, Zevia's model mirrors premium niche plays but scales via US mass-market channels, offering exposure to American wellness trends without European regulatory hurdles on sweeteners.

Recent Earnings and Strategic Developments

No major announcements mark March 13, 2026, but Q4 2025 highlights and Q1/Q2 2025 transcripts underscore margin expansion and distribution gains. August 2025 Q2 earnings revealed EPS losses narrower than expected, with record gross margins from cost controls and mix shift to higher-velocity SKUs. An equity distribution agreement for up to $20 million in August 2025 bolstered liquidity without dilution pressure at current levels.

Analyst actions include Telsey Advisory's upgrade to Outperform in early August 2025 and price target hikes to $2.70, though ratings mix Moderate Buy overall. Short interest declined 13.2% by June 2025, easing overhang. Upcoming Q3 2025 earnings on November 5, 2025, shifted focus to 2026 guidance, where volume recovery and international pilots could catalyze re-rating.

End-Market Demand and Competitive Landscape

The zero-sugar soda segment grows at double-digit rates, fueled by consumer pivot from Coke Zero and Pepsi variants seeking natural options. Zevia competes with Olipop, Poppi, and Olza, differentiating via stevia purity and kid-friendly lines. Walmart reinstatement coverage in February 2026 signals channel confidence, critical as retail comprises 80% of sales.

Risks include private label encroachments and promotional pricing wars eroding pricing power. European parallels emerge in Germany's sugar-reduced beverage mandates, where Zevia's formula aligns with EU health claims regs, potentially aiding future exports. DACH investors may value this as a proxy for domestic plays like Berentzen, but with superior US scale potential.

Margins, Cash Flow, and Balance Sheet Health

Gross margins hit records in Q1 2025, driven by supply chain efficiencies and reduced freight costs, a trend continuing into 2026 projections. Operating losses narrow as SG&A leverage kicks in above 100 million in annual revenue. Cash burn moderates post-equity raise, with no debt burden enabling focus on growth.

Capital allocation prioritizes distribution expansion over buybacks or dividends, suitable for a growth-stage firm. For conservative Swiss investors, the clean balance sheet mitigates downside, though path to free cash flow positivity remains 12-18 months out. Compared to peers, Zevia's 40%+ gross margins exceed industry norms, promising leverage if volumes rebound 5-10%.

Risks, Catalysts, and Sector Sentiment

Primary risks encompass consumer reversion to cheap sugars amid inflation, execution on new product launches, and liquidity squeezes during downturns. A pivot top sell signal from June 2025 lingers, with MACD caution. Catalysts include Q3 2025 print confirmation of trends, major retailer resets, and potential M&A interest from Big Soda seeking natural brands.

Sector peers like National Beverage report steady earnings, highlighting Zevia's turnaround narrative. Chart setup favors bulls near support, but high short interest history warrants caution. European angle: With DACH beverage firms facing energy cost pressures, Zevia's US-centric model insulates from local input inflation.

Investor Implications and Outlook

Zevia PBC suits speculative portfolios betting on health trends, with short-term technicals outweighing fundamentals temporarily. DACH investors gain US exposure via familiar brokers, benefiting from dividend-like yield via potential appreciation over eurozone staples. Monitor volume for trend confirmation; breaching $3.39 targets next leg higher.

Overall, the stock's high-risk/high-reward profile aligns with 2026's value rotation, but position sizing is key given volatility. Strategic focus on core sodas and expansions positions for multi-year compounding if execution holds.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.